Immunoprecise Antibodies Ltd. is advancing its universal dengue vaccine program. Following the discovery and validation of a uniquely conserved dengue epitope using its Lensai platform, the company is now advancing to preclinical manufacturing for in vivo testing and virus neutralization analysis.